Arch pushing anti-CD47 into new settings with $105M series C round

Arch Oncology, the latest CD47-focused biotech to draw big money with its $105 million series C round, plans to use its new capital to broaden the clinical development program for AO-176 and add new pipeline assets. 

New investors Eventide Asset Management and Cowen Healthcare Investments led the round alongside existing investors 3x5 Partners. ...